KindlyMD (NASDAQ:NAKA) Trading Up 15.8% - What's Next?

Key Points

• KindlyMD's stock experienced a 15.8% increase, reaching a trading price of $5.28 after closing at $4.56.
• Wall Street analysts have given KindlyMD a consensus rating of "Buy" with a target price of $8.00, according to a report from Maxim Group.
• The company reported a negative EPS of ($0.34) and a market capitalization of $3.23 billion, despite its focus on holistic pain management and combating the opioid crisis.

Shares of KindlyMD, Inc. (NASDAQ:NAKA - Get Free Report) were up 15.8% during mid-day trading on Tuesday . The stock traded as high as $5.42 and last traded at $5.28. Approximately 2,122,911 shares changed hands during mid-day trading, a decline of 29% from the average daily volume of 2,995,563 shares. The stock had previously closed at $4.56.

Wall Street Analyst Weigh In

Separately, Maxim Group started coverage on KindlyMD in a research report on Wednesday, September 3rd. They issued a "buy" rating and a $8.00 price objective on the stock. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $8.00.

KindlyMD Stock Down 29.4%

The company has a market cap of $1.05 billion, a price-to-earnings ratio of -3.23 and a beta of 33.96. The business's 50 day simple moving average is $9.16.

KindlyMD (NASDAQ:NAKA - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.34) earnings per share for the quarter. The company had revenue of $0.41 million for the quarter. KindlyMD had a negative net margin of 244.00% and a negative return on equity of 131.09%.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population.